Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ABT-510 in advanced head and neck cancer
NCT00113334Phase 2Completed
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Apr 2005
- Primary completion
- Mar 2008
- Countries
- 1
01
Overview
Phase 2, open-label trial of abt-510 in head and neck squamous cell carcinoma (HNSCC), sponsored by University of Texas MD Anderson Cancer Center. Primary endpoint: Objective Response Rate at 6 weeks. Started Apr 2005; status: completed.
02
Drugs
abt-510
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT00113334.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00113334.